• VIDEO: Opthea CEO discusses updates on OPT-302 for treatment of wet AMD

    2 monthes ago - By Healio

    CHICAGO - In this video from Eyecelerator AAO, Opthea CEO Megan Baldwin, PhD, discusses updates for OPT-302, a therapy targeting a new mechanism of action for the treatment of wet age-related macular degeneration.
    “We're excited about it because it targets VEGF-C and VEGF-D, which are not currently targeted by the existing standard of care treatments,” she said.
    Read more ...

     

  • VIDEO: SpyGlass CEO gives update on IOP-lowering drug delivery platform

    VIDEO: SpyGlass CEO gives update on IOP-lowering drug delivery platform

    2 monthes ago - By Healio

    CHICAGO - In this video from Eyecelerator AAO, SpyGlass Pharma CEO Patrick Mooney discusses the company's drug delivery platform, which lowered IOP in patients with open-angle glaucoma or ocular hypertension.
    “We're all about long-term drug delivery, and our long-term drug delivery platform gives the physicians the ability to treat patients and gives patients a little holiday from their drops,” he said.
    Read more ...

     

  • VIDEO: ViaLase shares safety, efficacy updates for glaucoma femtosecond laser

    VIDEO: ViaLase shares safety, efficacy updates for glaucoma femtosecond laser

    2 monthes ago - By Healio

    CHICAGO - In this Healio Video Perspective from Eyecelerator AAO, Shawn O'Neil of ViaLase discusses the company's noninvasive OCT-driven femtosecond laser for glaucoma treatment.
    In a case series of 18 eyes that underwent a procedure using ViaLase's femtosecond laser, 100% of patients experienced a greater than 20% IOP reduction at 24 months, with a 31% mean IOP reduction rate among the total cohort.
    Read more ...